prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, FINAL DIAGNOSIS: RIGHT BREAST AT 2 O'CLOCK, SEGMENTAL MASTECTOMY -. A. INELLTRATING DUCTAL CARCINOMA, NOTTINGHAM GRADE 1 (NUCLEAR GRADE 2, TUBULE SCORE 2,. MITOTIC ACTIVITY SCORE 1, TOTAL SCORE 5/9) (see comment). B. TUMOR MEASURES 0.7 CM IN GREATEST DIMENSION. C. NO DEFINITE LYMPHOVASCULAR INVASION IS IDENTIFIED. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 1, SOLID TYPE WITH CALCIFICATIONS. E. MARGINS ARE NEGATIVE; INFILTRATING CARCINOMA IS 0.8 CM FROM THE CLOSEST MARGIN; DCIS IS 0.1 CM. FROM THE INFERIOR MARGIN. F. ATYPICAL DUCTAL HYPERPLASIA. G. CHANGES CONSISTENT WITH PREVIOUS BIOPSY SITE. H. FIBROCYSTIC CHANGES. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Segmental. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 0.7 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinome. NOTTINGHAM SCORE: Nuclear grade. Tubule formation: 2. Mitotic activity score. Total Nottingham score: 5. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, malignant zones. TUMOR TYPE, IN SITU: Solid. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 8 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of in situ disease to closest margin: 1 mm. PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 0. METHOD(S) OF LYMPH NODE EXAMINATION: Other: N/A. T STAGE, PATHOLOGIC: pT1b. N STAGE, PATHOLOGIC: pNX. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: zero or 1+.

expanded version (tokens=1003) : 
 The breast pathology report contains the following information:

- Histological classification: The tumor is classified as infiltrating ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS).
- Subtype: The subtype of IDC is LumA (luminal A). However, there is no subtype mentioned for DCIS.
- Necrosis: There is no mention of necrosis.
- Tumor infiltrating lymphocytes: There is no mention of tumor infiltrating lymphocytes.
- Histological grade: The IDC is classified as Nottingham Grade 1, which is based on the nuclear grade, tubule score, and mitotic activity score. The nuclear grade is 2, tubule score is 2, and mitotic activity score is 1, resulting in a total score of 5 out of 9.
- Nuclear grade: The nuclear grade of the IDC is 2.
- Lymphovascular invasion: No definite lymphovascular invasion is identified.
- Calcification: The DCIS has calcification.
- Receptor status: The tumor is estrogen receptor-positive and progesterone receptor-positive. HER2/NEU has a score of zero or 1+.
- Ancillary testing results: No additional ancillary testing results are mentioned.

The main points from the report can be summarized as follows:

- The report describes a LumA subtype of IDC and DCIS in the right breast at 2 o'clock.
- The IDC is Nottingham Grade 1 with a

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=1163) : 
 The report reveals a LumA subtype of infiltrating ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS) in the right breast at 2 o'clock. The IDC is Nottingham Grade 1 with a nuclear grade of 2 and ductal carcinoma in situ showing solid type with calcifications. Distance of invasive tumor to nearest margin is 8 mm and DCIS is 0.1 cm from the inferior margin. The tumor is estrogen receptor and progesterone receptor-positive, but HER2/NEU status is indeterminate.

